Stephanie Reddin v. Kristi Noem - Employment Discrimination Appeal

The Fourth Circuit affirmed a lower court's dismissal of a former Federal Air Marshal's discrimination lawsuit against the TSA. The court found the plaintiff failed to adequately plead she was a qualified individual capable of performing essential job functions, and that the TSA had provided reasonable accommodations.

Heather Cogdell v. Reliance Standard Life Insurance - ERISA Disability Benefits

The Fourth Circuit Court of Appeals affirmed a lower court's decision in Heather Cogdell v. Reliance Standard Life Insurance Company. The court held that an untimely decision by a plan administrator on an internal appeal of a disability benefits claim, governed by ERISA, does not warrant deferential review.

United States v. Brian K. Griffey - Affirmation of Conviction

The Fourth Circuit Court of Appeals affirmed the conviction of Brian K. Griffey for violating supervised release terms. The court found the 24-month sentence imposed by the district court to be reasonable and not plainly unreasonable.

US v. Rashaun Taylor - Affirmance of conviction in part, dismissal in part

The Fourth Circuit Court of Appeals affirmed in part and dismissed in part the appeal of Rashaun Antonio Taylor. The court vacated Taylor's conviction on Count 3 (use of a firearm during a RICO conspiracy) and its attendant sentence, but otherwise affirmed the district court's denial of his motion for relief.

US v. Antionne Cherry - Sentencing Appeal

The Fourth Circuit Court of Appeals affirmed the sentence of Antionne Cherry, who appealed his conviction for being a felon in possession of a firearm. The court found that any error in calculating Cherry's sentencing guidelines range was harmless.

FDA Warning Letter to Kare Solutions LLC dba Zappy

The FDA issued a warning letter to Kare Solutions LLC dba Zappy for misbranding compounded drug products, including semaglutide, tirzepatide, and liraglutide. The agency found that Zappy's website made false or misleading claims about these products, suggesting they were FDA-approved or compounded by Zappy when they were not.

FDA Warning Letter to Strut Health, LLC

The FDA issued a warning letter to Strut Health, LLC on February 20, 2026, for misbranding compounded semaglutide and tirzepatide products. The company's website allegedly made false or misleading claims about these drugs, violating the Federal Food, Drug, and Cosmetic Act.

FDA Warning Letter to GenoGenix LLC

The FDA issued a warning letter to GenoGenix LLC for serious deficiencies in drug production practices, including failures to meet conditions for outsourcing facilities and insanitary conditions. The company has ceased production and initiated a voluntary recall of drug products.

FDA Warning Letter to Beta Bionics, Inc.

The FDA issued a warning letter to Beta Bionics, Inc. regarding violations of the Quality System Regulation for their iLet Dosing Decision Software and iLet ACE Pump. The letter details failures in corrective and preventive action procedures, including inadequate analysis of complaints leading to serious adverse health outcomes.

FDA Warning Letter to Diasol, Inc. for Medical Device Violations

The FDA issued a warning letter to Diasol, Inc. for manufacturing unapproved and misbranded medical devices, specifically disinfectants for hemodialysis systems. The company also violated Quality System Regulation requirements. The FDA has requested corrective actions to ensure compliance.